Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Researchers find a promising drug candidate for the treatment of ALS

A research group at the University of Helsinki and its partners have found a promising drug candidate for the treatment of amyotrophic lateral sclerosis (ALS). Cerebral dopamine neurotrophic factor CDNF prolongs the lifespan of and alleviates disease symptoms

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

A research group at the University of Helsinki and its partners have found a promising drug candidate for the treatment of amyotrophic lateral sclerosis (ALS). Cerebral dopamine neurotrophic factor CDNF prolongs the lifespan of and alleviates disease symptoms in rats and mice in animal studies.

Amyotrophic lateral sclerosis (ALS) is a rapidly progressing fatal neurodegenerative disease that affects the nerve cells in the brain and spinal cord. Specifically, a selective degeneration of motoneurons occurs in the spinal cord, leading to muscle atrophy and paralysis. Most patients with ALS die from respiratory failure, usually within 1 to 3 years from symptom onset. There is no cure for ALS, and the only drug available in Europe, riluzole, only prolongs ALS patient survival by a couple of months.

Assistant professor Merja Voutilainen and researchers from the Regenerative Neuroscience Group, Faculty of Pharmacy and Institute of Biotechnology, University of Helsinki, together with their national and international collaborators, investigated the therapeutic effect of a protein called cerebral dopamine neurotrophic factor (CDNF) in several cellular and animal models of ALS.

The CDNF protein, discovered by Professor Mart Saarma laboratory in 2007, is mostly found in the endoplasmic reticulum (ER) within cells. ER is an important cell organelle mainly involved in the synthesis and maturation of circa one-third of all proteins in the cell. CDNF has previously shown therapeutic potential in Parkinson's disease. In this study, the Regenerative Neuroscience Group used three animal models that were genetically modified to express human mutations (TDP43-M337V and SOD1-G93A) affecting ALS patients. Their goal was to investigate whether CDNF can affect disease development in the rodent models of ALS and elucidate its mechanism of action. They were particularly interested in studying ER stress, which is a cellular response to protecting cells and its proteins. If ER stress becomes chronic, as is the case in many neurological diseases, it can cause cell death.

We found that administration of CDNF to ALS mice and rats significantly improves their motor behavior and halts the progression of paralysis symptoms. Symptom amelioration is reflected in an increased number of surviving motoneurons in the spinal cord of the animals compared to rodents that did not receive CDNF. Our experiments suggest that CDNF may rescue motoneurons by reducing the ER stress response and, therefore, cell death. Importantly, ER stress was present in all our animal models, independently of the specific genetic mutations." Dr. Francesca De Lorenzo, lead author of the study, University of Helsinki

Professor Michael Sendtner from the University of Würzburg, Germany, one of the world's leading researchers in the field of ALS research and co-author of the study, comments: "This study opens the way to a rational therapy to counteract one of the most severe cellular pathologies in ALS: ER stress".

"CDNF holds great promise for the design of new rational treatments for ALS", says Dr. Merja Voutilainen, Assistant professor at the University of Helsinki and the director and senior author of the study.

De Lorenzo, F., et al. (2023). CDNF rescues motor neurons in models of amyotrophic lateral sclerosis by targeting endoplasmic reticulum stress. Brain. doi.org/10.1093/brain/awad087.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01ApconiX's in vitro seizure liability assay (iSLA) platform provides a human-relevant approach for assessing seizure liability. Where can AI add the most value alongside assays like this?

There are several areas where AI could add value, but one of the most exciting is helping us translate complex experimental results into actionable insights for drug discovery teams. We see computational and experimental approaches as complementary rather than competing technologies. In vitro assays such as iSLAseizure generate highly relevant biological data, while AI and machine learning can help uncover patterns within that data that might otherwise be difficult to identify. One example is work I recently presented at the BioNow BioAI Symposium, in which we explored the use of structure-activity relationships (SAR) and machine learning models alongside iSLAseizure assay data. Supported by colleagues, including Dr. Louisa Zolkiewski and Dr. Kim Rockley, ApconiX has developed an in-house seizure liability dataset that we analyzed in collaboration with MedChemica. Using machine learning and chemical informatics approaches, we identified chemical substructures that show statistically significant relationships with seizure-related outcomes. The aim is not simply to predict risk, but to understand which molecular features may contribute to that risk and provide medicinal chemists with practical guidance they can apply much earlier in the discovery process. Looking ahead, I think this is where AI can have a particularly powerful impact. Rather than acting as a standalone prediction tool, it can work alongside human-relevant assays such as iSLAseizure to connect molecular structure, experimental biology, and safety outcomes. That combination has the potential to improve decision-making earlier in the discovery process, reduce late-stage safety surprises, and ultimately support the development of safer medicines for patients.

Source: www.news-medical.net ↗
02What comes next?

We are now testing the drug in patients with earlier-stage pancreatic cancer, prescribing it while their tumors are still operable and before their cancer spreads.

Source: www.news-medical.net ↗
03What is carb cycling?

Carb cycling is an attempt to fine-tune your carbohydrate consumption to alter many aspects of your metabolism. Your plan will include the same protein intake each day but vary carbohydrates according to your activity. Your carb cycling plan may have three low or zero carb days, two moderate carb days, and two high carb days. Meeting your calorie requirements will require including more fats on low-carb days. Carb cycling needs much more planning than a usual calorie-controlled diet. One way is to match your carb cycling to your physical activity. If you go to the gym thrice a week, you could have carbs on those days. The carbs provide energy for your workout, prevent fatigue, and avoid the muscle loss sometimes seen with dieting. The days when you eat little to no carbs force your body to generate energy from other sources, like proteins and fats. But the days when you eat more carbohydrates might reverse this change. You must only eat a high-carb diet on the days you have a heavy workout, which uses up the calories.

Source: www.medicinenet.com ↗
04What do you think the future holds for deep learning with regards to drug discovery?

I think we're only just scratching the surface at the moment. I think over the next couple of years, we'll start to see some major strides. Obviously, showing the effects on target identification takes some time with new molecules but, certainly, the repositioning effects should be seen in a few years. I think there is great promise in terms of being able to really tap into a much broader chemical space, so we can have a much wider and more varied chemical palette to be able to pick the best molecules for drug discovery from. Also, accelerating the ways in which we can look at the data and glean much more information from it can help us both in terms of patient selection for clinical trials and in terms of being able to pick up signals of efficacy and safety much earlier.

Source: www.news-medical.net ↗
05What supplements really work?

The bulk of vitamins and supplements containing fish oil, biotin, and vitamins A, C, and E can potentially promote nail and hair growth. You can find dietary supplements with higher concentrations of vitamins and minerals that aid skin, hair, and nail health. Fish oil supplements make nails and hair shiny. Fish oil also serves as an agent that can decrease signs of aging. If sun exposure damages the skin, the omega-3 fatty acids in fish oil can help. Biotin, also known as B7, increases hair density and strengthens it. It is found naturally in bananas, eggs, and milk. Vitamins are vital for skin health as well. Vitamin A reduces acne flairs and helps with changes due to aging like wrinkling. A vitamin A deficiency may increase the risk of acne because it becomes difficult for dead skin to slough off hair follicles, blocking pores. Vitamin B lowers the risk of precancerous growths and nonmelanoma skin cancer. Vitamin C is an antioxidant. It leads the fight against free radicals to help stimulate collagen and brighten skin. It also helps to prevent the formation of unneeded melanin that causes uneven skin pigmentation.

Source: www.medicinenet.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →